

Australia's SpeedX increases distribution network

19 March 2021 | News

Partners with Neogen Diagnostik to expand sales



Australian firm SpeedX has announced signing a new distribution partner, further extending customer access to market-leading SpeedX **ResistancePlus**[®] and **PlexPCR**[®] tests. Neogen Diagnostik Sağlık Hizmetleri Ltd. Şti will distribute all SpeedX tests throughout Turkey.

"We continue to see demand for our key tests and technology around the world," says Warwick Need, SpeedX Director of Sales. "Neogen Diagnostik is a great fit for SpeedX products and we are looking forward to working with them to give Turkish laboratories the opportunity to provide ResistancePlus tests and support the use of Resistance Guided Therapy with their clinician partners."

In addition to **ResistancePlus** GC* - combining *Neisseria gonorrhoeae* (GC) detection with markers for ciprofloxacin susceptibility, and **ResistancePlus** MG* - simultaneously detecting *Mycoplasma genitalium* and genetic markers for azithromycin resistance, the SpeedX sexual health portfolio includes **PlexPCR** VHS* - a multiplex test for herpes simplex virus (1 and 2), varicella-zoster and *Treponema pallidum* (syphilis), and **PlexPCR** HSV-1&2, VZV.

SpeedX are also growing their Respiratory portfolio with the recently launched **PlexPCR** RespiVirus - a comprehensive multiplex panel for respiratory virus testing, and the soon to be launched **PlexPCR** SARS-CoV-2 test – a dual-target COVID-19 assay for confident detection of all currently known circulating variants. A respiratory bacterial infection testing solution will also be launched this year.

"Neogen Diagnostik is pleased to make Resistance Guided Therapy available to all stakeholders in the Turkey healthcare chain from clinicians and lab specialists to patients through this distributorship deal with SpeedX. This is absolutely of medical value complementing the rational use of antibiotics when treating patients. SpeedX solutions will be a real diagnostic tool for clinicians when deciding on the best possible treatment options for their patients," Abdulmecit Arikan, founder of Neogen Diagnostik, said in a statement.